LUNDBECK |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.4 DKK | +0.15% |
|
+9.83% | -6.20% |
| 05-15 | H LUNDBECK : Q1 beat adds momentum to the recent share price rally |  |
| 05-15 | Transcript : H. Lundbeck A/S, Q1 2024 Earnings Call, May 15, 2024 |
Presenter SpeechLars Rasmussen (Executives)[Interpreted] Welcome. So, welcome. On behalf of th...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimerâs disease, Bipolar disorder, depression, epilepsy, Huntingtonâs disease, Parkinsonâs disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimerâs disease, Azilect for the treatment of Parkinsonâs disease, Xenazine for the treatment of Huntingtonâs disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
37.4
DKK
Average target price
39.96
DKK
Spread / Average Target
+6.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.20% | 5.26B | |
| +21.93% | 73.38B | |
| -1.71% | 24.13B | |
| +7.33% | 8.78B | |
| +10.34% | 8.59B | |
| -19.80% | 8.06B | |
| -0.03% | 4.21B | |
| +12.70% | 4.17B | |
| -2.54% | 3.89B | |
| +24.00% | 3.71B |
- Stock Market
- Equities
- HLUN B Stock
- LUN Stock
- News Lundbeck
- Transcript : H. Lundbeck A/S - Shareholder/Analyst Call
